Clinical Trial Update: Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating rituximab plus cladribine (2-CdA) in advanced or relapsed mucosa-associated lymphoid tissue lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma of Mucosa-associated Lymphoid Tissue

Drugs mentioned

• Cladribine (cladribine)
• Rituximab (rituximab)

Snippet

Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie | Conditions: Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 2 | Status: COMPLETED